One NIST and 20 NIH Inventions Available for Licensing
NIST
The invention listed below is owned in whole or in part by the U.S. Government, as represented by the Department of Commerce. The Department of Commerce's ownership interest in the invention is available for licensing in accordance with 35 U.S.C. 207 and 37 CFR Part 404 to achieve expeditious commercialization of results of Federally funded research and development. NIST may enter into a Cooperative Research and Development Agreement (``CRADA'') with the licensee to perform further research on the inventions for purposes of commercialization.
Technical and licensing information on this invention may be obtained by writing to: National Institute of Standards and Technology, Office of Technology Partnerships, Building 820, Room 213, Gaithersburg, MD 20899; Fax 301_869_2751. Any request for information should include the NIST Docket No. and Title for the relevant invention as indicated below.
Invention: Device for Stable Speed Determination in Machining
NIST Docket Number: 99_016/025USThe device utilizes a non_contact force actuator to drive a machine_tool with a train of impulsive forces having a known, time_varying frequency to identify the speeds least likely to produce chatter (regenerative vibrations). This can be done in real time without the need for exhaustive cutting tests. The machine_tool spindle and a non_contact magnetic force actuator are used to produce the time_varying impulse train. This impulse train has significant energy at the spindle speed and its harmonics. As the spindle speed is ramped up from zero to the maximum speed, those speeds that maximize the dynamic response of the tool are the speeds that minimize regenerative chatter. The device is suitable for integration with the machine_tool controller, and could potentially allow the optimal speeds for each tool to be downloaded and stored for later use in NC programming.
NIH Inventions
Please note the points of contact for are listed above each set of inventions.The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally_funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting Girish C. Barua, Ph.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852_3804; telephone: 301/496_7056 ext. 263; fax: 301/402_0220; e_mail: BaruaG@od.nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
Invention #1 Compositions and Methods for Treatment of Breast Cancer__the Synergistic Effect of Farnesyl Transferase Inhibitors and Tamoxifen Combination Therapy
Geoffrey J. Clark, Joanne Zujewski (NCI)
Serial No. 60/171,928 filed 22 Dec 1999This invention discloses compositions that act in a synergistic manner to inhibit and or prevent breast cancer cell growth. Specifically, this invention discloses methods for treating and preventing breast cancer using a combination of selective estrogen receptor modulators (SERMs) and farnesyl transferase inhibitors (FTIs). The combination therapy comprising of at least one SERM and at least one FTI has shown enhanced therapeutic efficacy in killing cancer cells. Thus the combination therapy may lead to enhance efficacy of Tamoxifen or other SERM treatment regimes. For example, it is contemplated that the present invention will find use in a treatment therapy using lower doses of SERMs for a shorter duration. In some embodiments of the invention, therapeutic agents are administered to subjects suspected of having cancer or being susceptible to cancer, subjects with cancer, subjects experiencing a recurrence of cancer, or subjects who are post_operative for cancer. Additionally, the treatment agents could be administered prophylactically to patients at risk for development of cancer.
Invention #2 Tyrosyl_DNA Phosphodiesterases (TDP) and Related Polypeptides, Nucleic Acids, Vectors, TDP_Producing Host Cell, Antibodies and Methods of Use
Jeffrey J Pouliot, Howard A Nash (NIMH)
Serial No. 60/157,690, filed 05 Oct 1999Topisomerases are cellular enzymes that are vital for replication of the genome. However, if topisomerase and DNA form covalent complexes that prevent the resealing of DNA, this may lead to cell death. Essentially, this invention consists of a new isolated and cloned enzyme, tyrosyl_DNA phosphodiesterase (TDP1), that is capable of hydrolyzing the covalent complexes between topisomerase and DNA, allowing the DNA to reseal. The mechanism that defines topisomerases is their capacity to break DNA and, after an interval in which topological changes may occur, to reseal the break without the intervention of a high energy cofactor. The breakage of the DNA is accompanied by the formation of a covalent bond between topisomerase and DNA to create an intermediate that is resolved during the resealing step. However, if the resealing step fails, the covalent intermediates between topisomerase I and DNA can become complexes that lead to cell death.
The failure of the resealing is increased by some chemotherapies such as camptothecin. Thus, this technology has many potential commercial uses including: a method for screening camptothecin analogues or other compounds for their resistance to repair by this enzyme or to prescreen patients for their sensitivity to topisomerase inhibitors which could identify patients most likely to respond to camptothecin therapy.
Further, this invention provides for a vector comprising of the nucleic acid molecule for TDP1 as well as the method of altering the level of TDP1 in a cell, a tissue, an organ or an organism.
Finally, this invention consists of a method for identifying a compound that stabilizes a covalent bond complex that forms between DNA and topisomerase I, wherein the covalent bond cannot be cleaved.
Invention #3 Novel Vacuolar_Type (H+)_V_ATPase_Inhibitory Compounds, Compositions and Methods of Use
Michael R. Boyd (NCI)
Serial No. 60/122,953 filed 05 Mar 1999 and Serial No. 60/169,564 filed 08 Dec 1999The present invention relates to a new class of vacuolar_type (H\+\)_ATPase_inhibitory compounds. Vacuolar_type (H\+\)_ATPases (V_ATPases) have been described as a universal proton pump which are present in many tissues and cells of the human body. Vacuolar_type (H\+\)_ATPases are present intracellularly within certain organelles and are responsible for maintaining internal acidity thereof; V_ATPases are also located within specialized plasma membranes of certain cells, e.g. kidney intercated cells, osteoclasts and sperm cells. V_ATPases are important for a myriad of physiological functions such as: sorting of membrane and organellar proteins; proinsulin conversion; neurotransmitter uptake; receptor recycling; and cellular degradative processes. V_ATPase isoform_specific inhibitors may preferentially modulate V_ATPase activities in different cells and tissues, and may thereby provide diverse and distinctive pharmacological utilities.
Accordingly, the disclosed compounds and compositions may be used to inhibit such biological processes as: intra_organellar acidification, urinary acidification; bone resorption; fertility; tumor cell proliferation; and, drug resistance of tumor cells.
Licensing information and a copy of the U.S. patent application referenced below may be obtained by contacting J. R. Dixon, Ph.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852_3804 (telephone 301/496_7056 ext 206; fax 301/402_0220; E_Mail: jd212g@NIH.GOV). A signed Confidential Disclosure Agreement is required to receive a copy of any patent application.
Invention #4 Anti_EGFRvIII ScFvs with Improved Cytotoxicity and Yield, Immunotoxins Based Thereon, and Methods of Use Thereof
Drs. Ira H. Pastan (NCI), Richard Beers (NCI), Partha S. Chowdury (NCI) and Darell Bigner (EM).
USPA SN: [= DHHS Ref. No. E_009_00/0]__Filed with the U.S.P.T.O. on January 25, 2000.Abstract
A mutant form of the epidermal growth factor receptor, designated ``EGFRvIII,'' is highly expressed in some 50_60% of glioblastomas and has also been shown to be present in some 70_80% of carcinomas of the breast and ovary, and about 16% of non_small cell lung carcinomas. The mutation consists of an in_frame deletion of exons 2_7 near the amino_terminus of the extracellular domain which results in the expression of an EGFR mRNA with an 801 base deletion. The mutant protein contains a new glycine codon at the splice junction. The receptor has constitutive tyrosine activity that enhances the tumorigenicity of glioblastomas in vivo. Because of the tumor_specific extracellular sequence, the mutant receptor is an attractive potential target for cancer therapy, particular via the use of immunotoxins (e.g., MR1(Fv)_PE38).Technology
The technology claimed in the patent application is directed to antibodies to an epidermal growth factor receptor known as EGFRvIII. In particular, the invention provides an antibody, designated MR1_1, which mutates MR1 in the CDR3 of the (V<INF>H</INF>) and (V<INF>L</INF>) chains to provide an antibody with especially good cytotoxicity. The described polypeptides can be coupled, attached or otherwise linked to an effector molecule, therapeutic moiety, or detectable label. The patent application provides nucleic acid molecules encoding the polypeptides with a mutated antibody variable heavy (V<INF>H</INF>) chain regions or a mutated light chain (V<INF>L</INF>) region, or both. The invention also provides methods of killing a cell bearing an antigen comprising contacting the cell with an immunotoxin comprising a toxic moiety and a targeting moiety. The Antibodies and Immunotoxins of claimed in this patent application could be used to develop cancer therapeutics and diagnostics.
Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting Richard U. Rodriguez, M.B.A., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852_3804; telephone: 301/496_7056 ext. 287; fax: 301/402_0220; e_mail: rr154z@nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
Invention #5 Identification of a Novel Amplified Gene, MB1, at 17q23
Anne H Kallioniemi, Maarit T Barlund, Outi M Monni, Juha T Kononen, Olli P Kallioniemi (NHGRI)
DHHS Reference No. E_038_00/0 filed 13 Dec 1999DNA amplification at 17q23 is one of the most common genetic alterations in breast cancer. Genes affected by this amplification may have a critical role in breast cancer development and progression and may provide targets for anti_cancer therapy. The inventors have identified a novel gene from the amplified region, named MB1, which has no homology to any known genes. MB1 is amplified in about 9% of primary breast tumors and is overexpressed in breast cancer cell lines with amplification. MB1 may define a critically important breast cancer gene which could have significance for development of improved diagnostics against breast cancer.
Invention #6 The Use of Recombinant Cholera Toxin_B for the Treatment of Inflammatory Bowel Disease
Warren Strober, Monica Boirivant, Ivan J Fuss, Brian L Kelsall (NIAID)
Serial No. 60/165,111 filed 12 Nov 1999The present invention provides methods of treating or preventing inflammation in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B (CT_B). In particular, the present invention provides methods of decreasing the activity of interferon_gamma in a subject, decreasing the activity of IL_12 in a subject, and treating or preventing a Th1 T_cell mediated autoimmune disorder.
Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting Susan S. Rucker, J.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852_3804; telephone: 301/496_7056 ext. 245; fax: 301/402_0220; e_mail: sr156v@nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
Invention #7 Hybrid Adeno_Retroviral Vector for the Transformation of Cells
C Zheng, B O'Connell, BJ Baum (NIDCR)
Serial No. E_258_98/0 filed 31 Jan 2000The invention described and claimed in this patent application provides for novel hybrid vectors which may be used for cell transformation, either in vivo or in vitro. The hybrid vectors have an adenoviral backbone with retroviral long terminal repeats (LTRs). Such vectors are capable of transforming dividing or non_dividing cells and integrate stably into the chromosome providing a means of efficient, reliable, long_term gene expression. The vector was packaged as a recombinant adenovirus and delivered to the target cell. Unlike other chimeric or hybrid vector systems, only a single vector is required to deliver a transgene of interest, and retroviral structural proteins are not required.
This work has been published in part in Nature Biotechnology Zheng, et al. 18(2): 176_180 (Feb 2000).
Invention #8 Calcium Channel Compositions and Methods of Use Thereof
MI Lerman (NCI) et al.
Serial No. 09/470,443 filed 22 Dec 1999 and 60/114,359 filed 30 Dec 1998 (now abandoned)This invention described in this patent application relates to the identification, isolation and cloning of a three cDNAs identified during a search of the short arm of chromosome 3 for a tumor suppressor gene (TSG) associated with lung cancer. The cDNA's are alternative isoforms which encode a protein which functions as a subunit of L_type voltage_dependent calcium channel. Type L voltage_dependent calcium channels represent one of five families of calcium channels, L, R, P, N, Q, which have been identified. Type L voltage_dependent calcium channels are found in a wide variety of tissues including the brain, muscle and the endocrine system.
The gene has been mapped to the short arm of chromosome 3 at 3p21.3. The gene, which corresponds to this cDNA is an alpha2delta_2 (<greek_a>2<greek_d>_2) subunit, and has been shown to be deleted in lung and breast cancer. The scientists have demonstrated that the expression of this calcium channel has been shut off in lung cancer cells and hypothesize that this may lead to a malignant phenotype. Other cancers which may be associated with this <greek_a>2<greek_d>_2 subunit include cervical cancer and head and neck carcinoma. Other non_malignant diseases which may also be associated with this <greek_a>2<greek_d>_2 subunit include CNS diseases and cardiovascular diseases.
Possible applications of this technology include its use in drug screening assays; its use as an early diagnostic marker and/or as a prognostic or treatment indicator; its use in gene therapy where defective cells would be reconstituted with the gene and as a therapeutic agent for clearing autoantibodies which develop toward the alpha2delta_2 subunit in the disease Lambert_Eton myasthenia syndrome.
Invention #9 Monoclonal Antibody Against Met Protein
G Vande Woude, M Oskarsson, J Resau, S Rulong, Y Chui (NCI_FCRDC)
Serial No. 60/168,835 filed 03 Dec 1999The invention described in this application relates to the Hepatocyte Growth Factor/Scatter Factor/Tumor Cytotoxic Factor (HGF/SF/F_TCF)_met/Hepatocyte Growth Factor Receptor (HGFr) pathway. In particular, the invention described in this application is a murine monoclonal antibody, designated D1, which specifically binds to an epitope in the extracellular domain of human HGFr/met. The monoclonal antibody can be used, for example, to visualize HGFr/met expression in paraffin_embedded tumor samples and in drug screening assays (competitive binding assays) for antagonists/agonists of HGFr/met.
Invention #10 Determination of AM Binding Proteins and the Association of Adrenomedullin (AM) Therewith
F Cuttitta (NCI), A Martinez (NCI), R Pio (NCI), TH Elasser (USDA_ARS),
Serial No. 60/153,397 filed 10 Sep 99This application relates to isolation and identification of a polypeptide which binds to the hormone adrenomedullin designated adrenomedullin binding protein 1 (AMBP1). Adrenomedullin (AM), a peptide hormone, has been implicated in a variety of physiological functions including the regulation of insulin production, anti_microbial activity, mitogenesis and angiogenesis. The activities of AM are believed to be mediated by a variety of binding proteins in a manner similar to the way in which Insulin_like Growth Factor (IGF) is regulated. AMBP1 has been purified to homogeneity and its amino acid sequence determined.
The application is directed to methods of measuring AM levels in plasma based on the finding that AMBP1 binds in a specific and reversible competitive fashion with AM and methods of treating AM related disease by administering AMBP1. Other aspects of the invention are complexes of AM with AMBP1 and antibodies which specifically bind to an epitope by the complex of AM with AMBP1 as well as assays for detecting the complex of AM with AMBP1.
This work has been published in part in Elsasser TH, et al. Endocrinology 140(10):4908_11 (Oct. 1999).
In addition to being available for licensing the NIH is willing to consider interest from companies who are interested in pursuing commercialization opportunities through a Cooperative Research and Development Agreement (CRADA).
Invention #11 AAV5 Vector and Uses Thereof
JA Chiorini, RM Kotin (NHLBI)
Serial No. PCT/US99/11958 filed 28 May 1999 based on USSN 60/087,029 filed 28 May 1998The invention described and claimed in this patent application provides for novel vectors and viral particles which comprise adeno_associated virus serotype 5 (AAV5). AAV5 is genetically distinct from others AAVs with respect to its capsid proteins, VP1, VP2, and VP3, which contributes to different tissue tropisms for AAV5. The ITR and Rep proteins of AAV5 are also distinct which results in a biochemically unique mechanism of replication compared to the other AAVs. This difference in replication activity contributes to the fact that AAV5 is only able to replicate and package AAV5 ITR containing DNA in contrast to AAV2 which is able to replicate and package other AAV serotypes.
Vectors produced using AAV5 proteins may be useful in gene therapy AAV5 offers several advantages which make it attractive for use in gene therapy: (1) increased production (10_50 fold greater than AAV2); (2) its distinct replication mechanism when compared to AAV2; (3) its Rep protein and ITR regions which do not complement other serotypes; (4) it appears to utilize different cell surface attachment molecules than those of AAV type 2; and (5) improved efficiency of transduction of certain cell types including airway epithelial, striated muscle, endothelial, and neuronal cells when compared to AAV type 2.
This work has been published, in part, in J. Virol. 73(5): 4293_98 (May 1999) and J. Virol. 73(2): 1309_19 (Feb. 1999).
Invention #12 Prevention of Fetal Alcohol Syndrome and Neuronal Cell Death with ADNF Polypeptides
DE Brenneman (NICHD), CY Spong (NICHD), I Gozes (TAU), M Bassan (TAU), R Zamostiano (TAU)
Serial No. 09/267,511 filed 12 Mar 1999This patent application describes an extension of prior work related to peptides derived from proteins known as ADNF and ADNF III/ADNP. These peptides are known as SAL (ADNF_derived) and NAP (ADNP_derived). SAL and NAP (L_isomers) have previously been demonstrated, in in vitro work, to be able to prevent neuronal cell death and to protect against the toxic activities of a cholinotoxin suggesting that they are useful as therapeutics for neurodegenerative diseases. The new work presented in this EIR demonstrates that NAP and SAL (L_isomers), alone or in combination, prevent damage to neurons due to oxidative stress. In particular, the new work shows that NAP and SAL (L_isomers) alone or together are effective in preventing damage due to oxidative stress in a model for fetal alcohol syndrome. Thus, NAP and SAL (L_isomers), alone or together may be useful therapeutically to treat fetal alcohol syndrome.
In addition, a number of other patent applications and patents related to this technology have been filed by PHS and are available for licensing. These include: USP 5,767,240 (PCT/US92/03109); 08/324,297 (PCT/US95/12929); 60/037,404 (PCT/US98/07485); 09/187,330 (PCT/US99/26213) 60/149,956; and 09/364,609.
Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting Carol A. Salata, Ph.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852_3804; telephone: 301/496_7735 ext. 232; fax: 301/402_0220; e_mail: cs253n@nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
Invention #13 Molecular Clones With Mutated HIV GAG/POL and SIV Genes
George N Pavlakis (NCI)
Serial No. 60/173,036 filed 23 Dec 1999The invention is a DNA construct which can be used as part of an HIV DNA vaccine or as a lentiviral vector to deliver heterologous DNA to cells. The advantage of lentiviral vectors, over retroviral vectors, is that they can transduce quiescent cells, such as terminally differentiated neurons. The advantage of the lentiviral vectors of the invention over the lentiviral vectors of the prior art are that they can be highly expressed in human or mammalian cells in the absence of any other regulatory or structural protein of HIV, including REV. The advantage of vectors based on SIV is that they are divergent from HIV_1.
The construct encodes the gag/pol region of the HIV_1 genome in which the instability regions (INS) have been removed by multiple point mutations, without changing the protein sequence. The INS are regions in the unspliced RNA which decrease the amount of expression from the RNA, a decrease which is overcome by the interaction of the HIV protein REV with the RRE (Rev Response Element) found on the RNA constructs encoding gag, pol and env of HIV_1. Under certain situations the construct can result in the formation of infectious viral particles which contain only gag and pol from HIV. These viral particles can be used as vaccines or for gene therapy.
Invention #14 Time_Gated Imaging With a Split_Beam Source
Ronald W. Waynant (FDA)
Serial No. 60/153,100 filed 09 Sep 1999The present invention provides a new apparatus and methods for generating a split_beam electromagnetic source for imaging devices and methodologies. With this invention, one part of a split beam is used for generating an image of an object and another part of the split beam is used for timely capturing the generated image. The present invention offers many advantages over earlier technologies. For example: (1) switching with a short duration pulse allows for a fast time gate; (2) utilization of an electromagnetic pulse source to both image and time gate allows for easier and more precise synchronization of the time gate with the imaging source; and (3) optically switching the time gate solves the problem of jitter and inhomogeneous gating.
Invention #15 Identification of the Domain of Plasmodium falciparum Erythrocyte Membrane Protein (PfEMP1) that Mediates Adhesion to Chondroitin Sulfate A
Arthur Scherf et al. (NIAID)
Serial No. 60/152,023 filed 01 Sep 1999Plasmodium falciparum malaria is more severe in pregnant women and causes disease in the mother and fetal death, even in those women who were previously immune. Severe malaria during pregnancy is more common during the first pregnancy (primigravida) and much less after multiple pregnancies (multigravid). Pregnant women are infected by parasites that sequester in the placenta and such sequestration contributes to growth retardation, infant mortality and severe anemia. Multigravid women develop antibodies that block the adhesion of infected erythrocytes to their placental receptor, chondroitin sulfate A (CSA). This interaction is mediated by specific var (PfEMP1) genes that bind to the host receptor CSA. The domain of the CSA_binding var gene that mediates adherence to CSA has been identified. This domain and potentially other parts of the molecule can give rise to development of anti malaria vaccines and therapeutics that will protect women from placental malaria, particularly during their first pregnancy.
Invention #16 Method for Generating NMR Relaxation Data and Identifying Ligands to Target Molecules From Multiple Field NMR Spectra
David Fushman, Nico Tjandra (NHLBI), David Cowburn
Serial No. 09/385,227 filed 27 Aug 1999The present invention provides a nuclear magnetic resonance relaxation method of screening compounds for their ability to bind to target molecules and elicit site specific changes in the target molecule's structure. Specifically, this application pertains to a method of generating site specific nuclear relaxation data for target molecules and their ligands. These data can be used for exploration into the thermodynamic requirements of ligand binding, the calculation of structural constraints helpful in predicting the solution structure of a target molecule and its ligand complexes, and to design new ligands for target molecules.
Invention #17 Fast Displacement Encoding with Stimulated Magnetic Resonance Echoes by Sampling Both Components of a Stimulated Echo
Anthony H. Aletras, Han Wen (NHLBI)
Serial No. 60/147,314 filed 05 Aug 1999The present invention provides a nuclear magnetic resonance method of phase contrast motion encoding. This methodology samples both the simulated_echo and the simulated_anti_echo by means of multiple 180 degree refocusing radiofrequency pulses. The pulses produced by the disclosed methods are compatible for reconstructing images without the need for elaborate data processing steps. By combining this method with pulses with unequal first order moments, dynamic range of motion measurements, in the heart, can be extended within the time period of a breath_hold in humans. Utilizing this powerful new methodology, a variety of diagnostic information can be learned about cardiac function in normal and diseased states.
Invention #18 MRI Contrast Agents Depending on Proton Chemical Exchange
Robert S. Balaban, Kathleen Ward, Anthony H. Aletras (NHLBI)
DHHS Reference No. E_240_98/0 filed 21 Apr 1999Recently, methods have been developed to Magnetic Resonance Imaging (MRI) contrast using exogenous agents with exchangeable protons. These methods incorporate the use of selective reagents, such as sugars, amino acids, and nucleosides with appropriate proton exchange sites. Image contrast is generated by using saturation transfer techniques to selectively affect the water protons used in forming the MR image. The contrast agents developed do not contain metals or metal chelates. The agents have appropriate exchangeable proton sites which can be irradiated at known frequencies to obtain MRI images with specific contrast. This permits the image contrast to be turned off and on based on the irradiation scheme. This method also uses a controlled irradiation scheme to overcome the obstacle of broad proton resonance that limits contrast enhancement. In_Vivo data has shown the utility of this invention.
Invention #19 Oligomeric HIV_1 Envelope Glycoproteins
Patricia L. Earl, Chris C. Broder, Robert W. Doms, Bernard Moss (NIAID)
Serial Nos. 08/165,314 filed December 10, 1993; 08/805,889 filed March 3, 1997; 09/070,291 filed April 30, 1998; and 09/415,326 filed October 8, 1999This invention embodies a method for generating antibodies to HIV_1 envelope glycoproteins, which could hold powerful implications toward both the diagnosis and the treatment of AIDS. Specifically, the method involves the expression of a soluble protein, gp140, and the generation of antibodies to this protein. gp140 is a recombinant version of gp160, a protein which normally is cleaved in vivo to generate two glycoprotein subunits which are expressed on the surface of the HIV_1 envelope. Unlike previously isolated versions of gp160, gp140 is purified in a manner which preserves the quaternary structural elements of the protein. Due to the conserved nature of these structural elements, antibodies generated against gp140 may be more broadly reactive against various forms of AIDS than other antibodies generated to date.
Licensing information may be obtained by contacting J. R. Dixon, Ph.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852_3804 (telephone 301/496_7056 ext 206; fax 301/402_0220; E_Mail: jd212g@NIH.GOV). A signed Confidential Disclosure Agreement is required to receive a copy of any patent application.
Invention #20 Monoclonal Antibodies to Prostate Cells
Dr. Ira H. Pastan (NCI).
USP SN: 5,489,525 [= DHHS Ref. No. E_201_92/0]__Issued on February 6, 1996.Abstract
Prostate Cancer is a disease affecting approximately 1 million men in the U.S.A., with an annual incidence of around 179,000 and approximately 30,000 deaths per year. It is estimated that one_third of men over 50 will develop prostate cancer at some time in their lives. Control of primary tumor by surgical resection and/or radiation has proven effective in a number of cases, however, metastatic spread, primarily to the bone, especially at late hormone independent stages of the disease, has been more difficult to control and monitor. With the aging of the U.S. population, it has been estimated that the number of prostate cancer cases will increase dramatically.Technology
The technology disclosed in the 5,489,525 patent relates to a monoclonal antibody which is capable of binding to a cell surface differentiation antigen specific for prostate adenocarcinomas and other prostate cancer cells. Accordingly, methods of therapy can be employed with this monoclonal antibody to destroy prostate cancer cells, and hence, this monoclonal antibody may be useful in therapy and/or the diagnosis of prostate cancer. This monoclonal antibody can be produced by recombinant DNA techniques, the host cell being a eucaryotic or procaryotic cell, preferably a eucaryotic cell and more preferably mammalian. Hence, a monoclonal antibody, a recombinant monoclonal antibody, single polypeptide binding molecules, and binding fragments thereof coupled to molecules which are cytotoxic to prostate cancer cells (e.g., chemotherapeutic agents, prodrugs, cytotoxic or inhibitory peptides, cytokines, enzymes, diphtheria toxin, Pseudomonas Exotoxin, etc.) could be used to develop a prostate cancer therapeutic or diagnostic test system.
State Science & Technology Institute
5015 Pine Creek Drive
Westerville, OH 43081
Phone: (614) 901-1690
Fax: (614) 901-1696
Email: ssti@ssti.org© 2002 State Science and Technology Institute. All rights reserved.